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1. Introduction 
There is considerable interest in the development of marine based molecules 
for the treatment of a variety of human conditions including pain, cancer [1, 2], 
thrombosis [3] and a range of inflammatory diseases [2, 4-7].  In the context of 
inflammatory diseases, the rationale for this development is the unequivocal 
demonstration that endogenous glycosaminoglycans (GAGs), like heparin, can 
modulate inflammatory responses in vivo [8]. In addition, these anti-inflammatory 
properties can be mimicked by non-anticoagulant species of heparin such as O-
desulfated heparin [9, 10].  Heparin is a polysaccharide that acts via a wide range of 
anti-inflammatory mechanisms, which makes it a broad spectrum anti-inflammatory 
drug in addition to, and independent of, its anticoagulant activities [11].   The 
discovery of novel polysaccharides that share the anti-inflammatory actions of 
heparin, whilst lacking anticoagulant activity, provides the basis for the development 
of a novel class of anti-inflammatory drugs. The ability of heparin to bind to certain 
adhesion molecules that are integral to the inflammatory process, like P- and L-
selectin, is to a large extent dependent on the protein surface charge distribution and 
the complementary sulfation pattern of the heparin [12, 13].  For example, heparin 
binding to P- and L-selectin prevents leukocyte adhesion to vascular endothelial cells, 
and hence, transmigration to inflammatory sites [2, 14]. Additionally, heparin shows 
other anti-inflammatory activities, the precise mechanism(s) of which are not yet fully 
understood [15]. 
 
The anti-inflammatory activity of heparin and related molecules has been 
tested in numerous clinical trials with some success [15], although to date only 
pentosan polysulfate is approved for the clinical treatment of an inflammatory 
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condition, interstitial cystitis [16], and as an  intra-articular treatment for osteoarthritis 
in veterinary medicine.  Nonetheless, there is increasing evidence supporting the use 
of heparin like molecules in the treatment of inflammatory conditions of the 
respiratory tract.  For example, heparin has been shown to be effective in patients with 
chronic obstructive pulmonary disease (COPD) [17], asthma [18] and allergic rhinitis 
[19]. However, the anticoagulant properties of heparin limit the wider therapeutic 
utilisation of this drug in the treatment of inflammatory diseases, where anticoagulant 
activity is usually not desirable. Whilst the topical administration of heparin to 
mucosal surfaces in the respiratory tract is associated with limited systemic 
anticoagulant activity [20],  the development of a non-anticoagulant molecule 
mimicking the anti-inflammatory effects of heparin would be preferable.  Examples of 
this approach already exist and include a heparin-derived hypersulfated disaccharide 
that is effective against allergic inflammation in subjects with asthma [21].   
Traditionally heparin is prepared from porcine and increasingly bovine 
sources. However, there are cultural sensitivities surrounding the use of porcine 
products in some communities and with the use of bovine-based material, a possibility 
of adverse effects exists, e.g. the occurrence of spongiform encephalopathy (BSE).  
Therefore a number of marine based polysaccharides has been evaluated for their anti-
inflammatory activity [6, 22], as these eliminate the challenges and risks associated 
with molecules sourced from mammals [23]. One of the polysaccharides that has 
often been extracted from marine sources is dermatan sulfate, another member of the 
GAG family that has been shown to have anti-inflammatory properties, as well as 
being shown to participate in cell growth, differentiation and morphogenesis, cell 
migration and infections from bacteria and viruses [24]. Mammalian dermatan sulfate 
has been suggested as a potential alternative to heparin as it exhibits lower 
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anticoagulant activity than heparin and therefore its use poses a smaller risk of 
hemorrhage [25]. Dermatan sulfates with a variety of degrees and patterns of sulfation 
have been identified in the past in Ascidians, but some of these polysaccharides have 
been shown to also have anticoagulant activities [26, 27]. 
 
Chitin is an unsulfated marine derived polysaccharide, one of the most 
abundant polysaccharides on earth, and the most abundant renewable polymer in the 
oceans. It is a linear polysaccharide consisting of β-1,4-Ν-acetyl-D-glucosamine 
monosaccharide units. The main role of chitin is to participate in the construction of 
protective tissues like the exoskeleton of arthropods, e.g. shrimps and lobsters, as well 
as the cell walls of fungi and the exoskeleton of insects [28]. However, chitin can also 
participate in the formation of signalling molecules, for example the lipochitin 
oligosaccharides that are produced by rhizobia [29]. The fucosylation of the C6 of the 
reducing end N-acetylglucosamine by the NodZ chitin oligosaccharide 
fucosyltransferase has been shown to extend the range of hosts for certain bacteria 
[30]. Aberrant fucosylation of the GlcNAc moieties of glycoproteins has been 
reported in several types of cancer [31]. In general, the fucosylation of various 
glycoproteins has been observed in a multitude of different organisms, from insects to 
animals [32, 33], and has been suggested to be responsible for the regulation of 
various biological activities [34, 35].  
 
Here we present the structural analysis and pharmacological properties of two 
novel polysaccharides (VRP327A & B) isolated from the ascidian (more commonly 
named sea squirts) Ascidiella aspersa 
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2. Materials and methods 
 
2.1 Materials 
Ethylenediaminetetraacetic acid (EDTA) and trimethylsilyl propionate (TSP) were 
purchased from Goss Scientific Instruments Ltd and Aldrich respectively. The sea  
squirt Ascidiella aspersa was obtained from Loch Fyne Seafarms (Tarbert, Loch 
Fyne, Scotland), where the tunic was removed and discarded, and the remainder of the 
animal stored frozen (-20 °C). 
Fucoidan from F. vesiculosus was obtained from Glycomix Ltd, Reading, UK. 
 
2.2 Extraction of Polysaccharides from sea squirts 
 
Extracts were prepared by digestion of approximately 20 kg of homogenized tissue 
with alcalase (5 ml/kg wet weight, Novozymes) for 16 h at 60 °C, pH 8.0 with 
continuous stirring. The polysaccharides were recovered from the strained liquor by 
mixing with pre-equilibrated anion exchange resin (1:1 mixture of Lewatit 
VPOC1074 and S6328A, Caldic, UK), 200 g / kg marine tissue. The eluted product 
was then cleaned-up by further size-exclusion (Sephacryl S100, GE) and ion 
exchange (Q Sepaharose FF, GE) chromatography. The final product was dried by 
lyophilisation or spray drying.  
 
2.3 Free radical depolymerisation of polysaccharide B 
 
The polysaccharide sample was in some cases subjected to free radical 
depolymerisation based on the method of Volpi [36]. The polysaccharide (60 mg) was 
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dissolved in water (25 ml) and the solution was brought to 50 °C following addition 
of Copper (II) acetate (monohydrate) (50 mg). The pH was adjusted to a value 
between 7.5 and 8 using NaOH. The depolymerisation was then initiated by 
continuous addition (using syringe pumps) of hydrogen peroxide and sodium 
hydroxide, with flow rates adjusted to maintain pH 7 – 8. On completion of the 
depolymerisation, the reaction was stopped by adding 20 % acetic acid and Chelex. 
The final solution was cleaned-up by preparative chromatography on Q-Sepharose to 
remove the Copper, and fractionated on sephacryl S30 before lyophilisation. 
 
2.4 Molecular weight determination 
 
The molecular weight (MW) of finished products was determined by high 
performance liquid chromatography (HPLC), size exclusion chromatography (SEC) 
with refractive index (RI) and/or photodiode array detection (PDA). Samples were 
analysed using both a Biosep SEC 4K column (300 x 7.80 mm, Phenomenex), which 
has a higher molecular weight range (determined as 12 kDa to 670 kDa), and if 
necessary a YMC Diol 120 (250 x 4.6 mm, YMC Europe) column which has a lower 
molecular weight range (determined as 1,340 Da to 8,040Da). Both columns were 
calibrated with standard dextrans (Fluka) run under the same conditions. Samples 
were prepared at 1 mg/ml in the mobile phase (1 mM EDTA, 0.9 % NaCl, 50 mM 
Tris, pH 7.0) and 20 µl injections were analysed over 15 min using a Waters 2695 
HPLC system running at 1 ml/min with a column temperature of 30 °C. Data were 
collected by RI and PDA (190-400 nm).  
 
2.5 Uronic acid determination 
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The uronic acid content was determined after acid hydrolysis (6.0 M HCl at 100 °C 
for 6 h) by the modified carbazole reaction as previously described [37].  
 
2.6 Protein Content determination 
 
Protein content was determined using a Pierce 660 nm protein assay (Thermo) in 
accordance with manufacturer’s instructions. Calibration curves were constructed 
using bovine serum albumin (Sigma) standard solutions. 
 
2.7 Sulfate Assay 
 
We used a previously described technique for the determination of small amounts of 
sulfate present in GAGs [38]. To minimise the amounts required of each valuable 
sample, the method was miniaturised for use in a microplate format. Samples were 
hydrolysed by mixing a 1 mg/ml solution in water (25 µl) with an equal volume of 1 
N HCl and heating for 1-2 h at 100 °C. The hydrolysed samples were dried in a 
vacuum centrifuge at 60-65 °C. The dried hydrolysate was reconstituted in deionised 
water (250 µl). Matching, non-hydrolysed samples were run alongside the hydrolysed 
samples, at a concentration of 1 mg/ml. Sulfate content was determined by mixing 
each sample (100 µl) with ethanol (400 µl) in a microfuge tube and this mixture (125 
µl) was then added to a 96-well microplate. BaCl2 buffer (50 µl) was then added to 
each well followed by sodium rhodizonate solution (75 µl). The microplate was 
shaken for 30 sec on a plate shaker and then incubated in the dark at room 
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temperature for 10 min, followed by a further 30 sec shake and final measurement of 
colour intensity using a plate reader set to 520 nm. 
 
 
2.8 Disaccharide Analysis 
 
The disaccharide composition of the polysaccharide was determined by HPLC using 
an established [39]. Samples were digested at a final concentration of 5 mg/ml in 
digest buffer (0.5 mM Tris 0.01 mg/ml BSA 5mM NaCl pH 7.0) with 1.4 mU of 
heparinase II (Grampian Enzymes) or 2.5 mU of chondroitinase ABC (Grampian 
Enzymes), overnight at 25 °C. Samples were analysed with and without hydrolysis in 
order to identify free disaccharides which might lead to misinterpretation of the 
disaccharide composition. Heparin (Acros) and shark chondroitin sulfate (Sigma) 
were used as control enzyme substrates. The digested samples were analysed by 
HPLC strong anion exchange chromatography using a ProPac PA1 Analytical column 
(4 x 250 mm, Dionex) and a Waters 2695 separation system equipped with a PDA 
detector. Standard heparin and chondroitin disaccharides (Dextra Labs) were used for 
calibration purposes. The digested samples and controls were loaded (20 µl) and 
eluted with a salt gradient (buffer A, dH2O pH 3.5) rising to 60 % buffer B (2M NaCl 
pH 3.5) after 30 min, monitoring at 232 nm. 
 
2.9 Monosaccharide analysis 
 
The monosaccharide composition of samples was determined by methanolysis / TMS 
derivatisation followed by gas chromatography with flame ionisation detection. The 
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sample (0.1 mg) was mixed with scyllo-inositol internal standard (5 nmol) and was 
treated with 100 µl 0.5 M methanolic HCl in an oven-treated sealed glass reacti-vial 
for 4 h at 85 °C. After cooling, neat pyridine (20 µl) was added to neutralize the HCl, 
mixed, and neat acetic anhydride (20 µl) was added to re-N-acetylate any free primary 
amines. The samples were dried overnight in a vacuum centrifuge, followed by 
addition of methanol (40 µl), after which they were dried again for 2 h. Samples were 
reacted with Tri-methylsilane reagent (TMS, 40 µl, Supelco) in sealed reacti-vials for 
10 min. Samples were analysed by GC-FID: 1 µl injections were analysed on a 
Shimadzu GC-2014 machine with FID using a ZB5-ms column (30 m x 0.25 mm id x 
0.25 µm film thickness) at 300 °C. Monosaccharide standards were prepared and 
analysed in the same way: arabinose (A3131 Sigma) xylose (X-1500 Sigma), 
mannose (M6020 Sigma), fucose (F2252 Sigma), rhamnose (R3875 Sigma), galactose 
(G0750 Sigma), glucose, glucosamine (G4875), galactosamine (G0500), glucuronic 
acid (G5269), galacturonic (48280 Fluka) and sialic acid were all prepared as 100 mM 
stock solutions. Monosaccharide composition of samples was determined on the basis 
of peak areas with a response factor calculated from the peak area for each 
monosaccharide standard relative to the internal control. 
 
2.10 FTIR spectroscopy 
 
Transmission FTIR spectra were collected for selected samples and reference 
compounds (chitin, dermatan sulfate and chondroitin sulfate B, all obtained from 
Sigma) prepared in potassium bromide tablets. Transmittance data were analysed 
using Essential FTIR software. 
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2.11 Cell viability 
 HeLa cells were grown under standard tissue culture conditions (37 °C, 5% CO2), 
until a 90 % confluent monolayer was achieved.  The cells were then trypsinized, 
transferred into a tube and centrifuged (200 g) to form a pellet, and re-suspended in 
growth media and then added to a microplate (4 x 103 cells/well; 100 µL). Cells were 
incubated in the absence or presence of sea squirt polysaccharides for a period of 24 h 
at 37 °C, 5 % CO2   XTT labelling reagent and electron-coupling reagent from the cell 
proliferation kit (Cell Proliferation kit II (XTT), Roche) was added to the wells (50 
µL) for a period of 4 h at 37 °C, 5 % CO2.  Absorbance was measured at 492 nm with 
a reference wavelength of 690 nm.  The percentage viability of cells was expressed as 
the absorbance of test agents as a percentage of control values.   
 
2.12 Anticoagulant activity 
 
Characterization of the anticoagulant activity (anti-factor IIa, anti-factor Xa, activated 
partial thromboplastin time (APTT) and heparin cofactor II (HCII) assays) of the sea 
squirt samples was performed using a previously published protocol  [40].  
 
2.14 Pre-kallikrein activation assay 
 
In order to investigate the interaction of the sea squirt polysaccharides with the 
contact activation pathway, a pre-kallikrein activation assay was carried out as 
previously described [40]. Briefly, a dilution series of the samples and a dextran 
sulfate (Leuconostoc mesenteroides, Sigma) positive control were set up, and each of 
the seven concentrations was mixed with normal pooled plasma (George King Bio-
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Medical Inc.) as described elsewhere [41]. After a 5-min activation period at 37 °C, a 
chromogenic substrate specific for plasma kallikrein was added (Chromogenix 
S2302), and color development, indicating substrate cleavage, was measured after 4 
min (A405–490 nm). The change in absorbance was compared with a blank control 
related to the amount of kallikrein in the blood resulting from pre-kallikrein activation 
by test samples. Four runs were carried out, and a concentration-response curve was 
generated for each sample. 
 
2.15 Elastase release from human neutrophils 
 
Human neutrophils were isolated from whole blood isolated from the antecubital vein 
of healthy volunteers using citrate as an anticoagulant. Ethics permission was 
obtained from National Research Ethics Service – North of Scotland, for these 
experiments. Neutrophils were isolated using a previously described technique [42-
46], washed and suspended in HBSS (PAA) at a final concentration of 2.5 x 106 
cells/ml.  This cell suspension (150 µl) was added to microtubes containing HBSS (22 
µl; PAA), cytochalasin B (25 µl, 40 µg/ml; Sigma) and TNFα (25 µl 80 ng/ml; Merck) 
to give a final concentration of 5 µg/ml and 10 ng/ml, respectively for 30 min at 37 °C 
in the absence or presence of increasing concentrations of a novel marine 
polysachharide.  The formyl peptide ligand, f-met-leu-phe (fMLP)(25 µl, 100 ng/ml; 
Sigma) was then added and cells incubated for a further 45 min at 37 °C.  The micro 
tubes were then centrifuged (5000 rpm; 2000g) for 5 min to pellet the cells and the 
supernatant (25 µl) added in triplicate to a 96-well microplate for the determination of 
measurement of elastase release.  In brief, Tris buffer (150 µl, 0.1M) and neutrophil 
elastase substrate 1 (MeOSuc-Ala-Ala-Pro-Val-pNA; 20 µl, 0.5 mg/ml; Merck) were 
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added to each well and absorbance measured at 405 nm every 5 min for 1 h and V 
max calculated over 4 data points between 10 min and 1 h.  Data are expressed as 
percentage of control samples. 
2.16 Neutrophil adhesion assay 
 
Human umbilical vein endothelial cells (HUVEC) (Promocell) were cultured in 
accordance with the supplier’s instructions and grown to confluence in flat-bottomed 
96-well cell culture plates. Human neutrophils were isolated from fresh whole blood 
obtained from the antecubital vein of male healthy volunteers as described above and 
stained with Calcein AM (Invitrogen) by adding the Calcein AM (12.5 µl, 1 mg/ml 
stock) in DMSO to 3.6 x 107 cells (5 ml) to give a final concentration of 2.5 µM. The 
cells were incubated at 37 °C, 5 % CO2 for 30 min and centrifuged at 400 g for 10 
min. The resulting cell pellet was washed 2-3 times by re-suspending in HBSS (5-
10ml) followed by centrifugation. After the final wash, cells were re-suspended into 
HBSS at a density of 1 x 106 cells/ml. HUVECs were stimulated prior to addition of 
labelled neutrophils by the addition of 10 Uml-1 IL-1β and TNFα, followed by a 6 h 
incubation at 37 °C, 5 % CO2. The HUVECS were then washed with HBSS followed 
by addition of 2 x 105 labelled neutrophils to each assay well. Three test plates were 
run in parallel: unstimulated HUVECs with no test compounds, stimulated HUVECs 
with no test compounds, and stimulated HUVECs with test compounds added. The 
plates were incubated for 15 min at 370C in 5% CO2 after which non-adherent cells 
were removed by washing 2-3 times with assay buffer. The plates were then read by 
measuring fluorescence using 485/530 nm excitation/emission filter sets on a Biotek 
Synergy 2 plate reader. Data were expressed as percentage adhesion relative to 
controls. 
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2.17 Neutrophil migration assay 
HUVECs (Promocell) were cultured in accordance with the supplier’s instructions 
and grown to confluence in tissue culture flasks. The endothelial cells were released 
from the culture flasks by trypsinisation (HUVEC Detach Kit, Promocell), and re-
suspended in pre-warmed endothelial growth medium at a concentration of 3 x 105 
cells/ml.  A HUVEC suspension (100 µl) was added above the transwell filter (24-
well Thincert Plates, Greiner) of each well in the plate and media (600 µl) below the 
filter and incubated at 37 °C, 5 % (V/V) CO2, until a confluent monolayer of cells was 
formed. Neutrophils were isolated from fresh whole donor blood and stained with 
calcein AM as described above. The HUVECs were stimulated by adding to each well 
IL-1β (11 µl of 0.2 µg/ml) and TNFα (11 µl of 0.2 µg/ml) to achieve final working 
concentrations of 0.01 µg/ml IL-1β and TNFα. The wells were treated with HBSS (22 
µl) and all wells were incubated for 6 h at 37 °C, 5 % (V/V) CO2. On completion the 
transwell filters were transferred to an empty 24 well plate. The media from below the 
well was removed and rinsed out once with HBSS, before adding fresh HBSS (600 
µl) to the lower chamber. The media from above the filter was gently removed and the 
HUVECs washed carefully using HBSS (200 µl). The filters were returned to the 
original 24 well plate containing the fresh HBSS and 22 µl of 10X the test compound 
was added shortly thereafter, followed by stained neutrophils (100 µl) into the top 
chamber, bringing the volume up to 222 µl. IL-8 was used as the chemoattractant, by 
adding IL-8 (60 µl of 1 mg/ml stock) to the lower chamber, and HBSS (60 µl) to the 
lower chamber in all other groups. In a separate 24 well plate, labelled neutrophils 
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(100 µl) were added to HBSS (600 µl). The plates were then incubated for 90 min at 
37 ºC in 5 % CO2 to allow cells to migrate. In order to remove test cells with non-
specific binding from above the filter, the media and cells from above the filter were 
transferred to a 96 well solid black plate. Each filter was gently washed twice with 
HBSS (200 µl) and transferred to the black 96 well plate.  The fluorescence from this 
fraction is referred to as the non-adherent component. The filters were transferred to a 
solid black 24 well plate to be read, with this being referred to as the adherent 
component. The media in the lower chamber was transferred into a solid black 96 
well plate and the well was rinsed with HBSS, which was also then transferred to the 
96-well black plate. The fluorescent reading from this fraction is referred to as the 
migrated component.  All readings were blanked by reading wells containing HBSS 
only and the filter readings were blanked with a clean wet filter. The media from the 
well on the separate control 24 well plate containing the neutrophils was transferred to 
a solid black 96 well plate and read to provide a control for the total fluorescent value 
of labelled cells. Fluorescence was read as described above.  
 
 
 
2.18 In vivo peritoneal inflammation model 
  
Male BALBc mice (6 -8 weeks; 20-22 g) were obtained from King’s College London 
and maintained on a 12 h light/12 h dark cycle, and were allowed food and water ad 
libitum.  Animals were housed in standard caging (5 mice per cage) with appropriate 
bedding and enrichment.  All of the experiments undertaken within this study were 
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approved under the Animals [Scientific Procedures] Act (1986) and carried out in 
accordance with the ARRIVE guidelines.   
 We utilized a modification of our previously published method to assess 
neutrophil recruitment to the peritoneal cavity of mice [47] to investigate the effect of 
the sea squirt polysaccharides.  Mice were randomized to receive an intravenous 
injection of either saline control or test substance. After 15 min of vehicle or test 
substance, zymosan A (0.5 ml; Sigma Chemical) was injected intraperitoneally to 
give a total dose of 1 mg/mouse. Four hours later, mice were killed by an overdose of 
CO2 and 3ml of saline was injected into the peritoneal cavity. The peritoneal cavity of 
each mouse was then massaged for 1 min and a small incision made to the lower 
abdomen to reveal the peritoneal cavity, and lavage fluid (2ml) was collected and 
stored on ice. Total and differential cells counts were enumerated. A dose response 
relationship was undertaken to assess the in vivo potency of these molecules as anti-
inflammatory agents in vivo. 
 
2.19 Statistical Analysis 
 
Statistical analysis was performed using Graphpad prism (Graphpad, version 5).  The 
null hypothesis was tested using analysis of variance for grouped data and an 
appropriate post-hoc test was applied; the mean values were considered significantly 
different when p < 0.05.  In other instances, dose response data were fitted to a 3 
parameter logistic equation to determine potency.  Data are expressed as mean + sem. 
 
2.20 NMR analysis  
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All lyophilized samples were dissolved in 100 % D2O (540 µl) containing deuterated 
NaH2PO4+HNa2HPO4 buffer (10 mM, pH 7.2). A stock solution of EDTA and TSP 
(20 µl) was then added. The stock solution was prepared by dissolving EDTA (4 mg) 
and TSP (9 mg) in the phosphate buffer (200 µl). The pH was adjusted to 7.2 by 
adding a few drops of a concentrated solution of NaOH in D2O. All spectra were 
acquired at 50 oC on an 800 MHz Avance I (Bruker) NMR spectrometer equipped 
with a z- gradient triple-resonance TCI cryoprobe. The spectra were referenced using 
1H and 13C signals (0 ppm) of TSP.  
 
1D 13C NMR spectra were acquired using relaxation and acquisition times of 1.5 and 
0.185 s; 40960 scans were accumulated in 20 h per spectrum. FIDs were zero filled 
once and a 2 Hz exponential line broadening was applied prior to Fourier 
transformation.  2D 1H, 13C HSQC spectra were acquired using t1 and t2 acquisition 
times of 22 and 106 ms, respectively; 10 scans were acquired into each of 800 F1 
complex data points resulting in the total experimental times of 3.5 h per sample. The 
standard 2D 1H, 13C HSQC-TOCSY BRUKER pulse sequence was modified by 
appending a 1H spin-echo of overall duration of 1/1JCH (optimized for a 1JCH =150 Hz) 
after the TOCSY spin-lock and two 2D 1H, 13C HSQC-TOCSY spectra were acquired 
in an interleaved manner. The first with, and the second without, an 180o 13C pulse 
applied simultaneously with the 180o 1H pulse of the final spin-echo. This resulted in a 
change of the sign of one-bond cross peaks between the two spectra.
  
Addition of the 
two 2D matrices prior to processing yielded a 2D 1H, 13C HSQC-TOCSY spectrum 
with substantially reduced one-bond cross peaks. Such treatment has facilitated 
identification of weak TOCSY cross peaks. The subtraction of the two original 
spectra yielded a 1H, 13C HSQC spectrum. Each 2D 1H, 13C HSQC-TOCSY spectrum 
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was acquired using t1 and t2 acquisition times of 44 and 106 ms, respectively; 1600 
complex data points using 24 scans were collected in F1 in each experiment; the total 
duration of the experiment was 18 h. Spin-lock was achieved via DIPSI-2 mixing 
sequence applied for 25 or 60 ms. 2D 1H, 13C HSQC-NOESY spectra for the 
polysaccharides were acquired using t1 and t2 acquisition times of 21 and 106 ms; 750 
complex data points were collected in F1 using 192 scans; the total duration of the 
experiment was 66 h.  The NOESY mixing time was 25 ms. 2D 1H, 13C HMBC 
spectra for the VRP 327B oligosaccharides were acquired using t1 and t2 acquisition 
times of 14 and 367 ms; 1024 complex data points were collected in F1; the total 
duration of the experiment was 8.5 h. The experiment was optimized for the nJCH of 6 
Hz and a two-stage one-bond correlation filter was set for 1JCH of 120 (minimum) and 
160 (maximum) Hz.  
 
3. Results and discussion 
3.1 Monosaccharide analysis of the sea squirt samples. 
 
The initial sea squirt samples analysed contained a mixture of polysaccharide A and B 
(43% of A and 48% B polysaccharides, respectively which we have designated as 
VRP327A and VRP327B) (Table 1). Due to size and charge similarities between 
polysaccharide A and B it was not possible to separate them fully. Nevertheless, 
NMR was able to guide the HPLC purification process, resulting in two samples, one 
of them containing 83% polysaccharide A and 13% B, with another one containing 
20% polysaccharide A and 73% B. 
 
Table 1: Monosaccharide analysis of three sea squirt samples 
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Monosaccharide Polysaccharide A 
rich sample 
Polysaccharide B 
rich sample 
Initial sample 
Arabinose 0 0 0 
Rhamnose 0 3.45 2.58 
Fucose 4.28  25.16 18.71 
Xylose 0.8  0.84 1.3 
IdoA 40.92  9.85 24.5 
Mannose 0 0.42 1.22 
Galactose 2.54  1.67 2.72 
Glucose 0.55  0.48 0.68 
GlcA 1.61  1.28 1.91 
GalNAc 40.9  8.54 16.91 
GlcNAc 8.4  48.31 29.47 
 
Both polysaccharides A and B had molecular weights > 100 kDa. In the initial 
monosaccharide analyses we performed, it was not possible to distinguish IdoA, 
which is found in DS, from GlcA, which is found in CS, due to lack of availability of 
appropriate IdoA standards.  However, in the last 2 batches analysed, it was possible 
to distinguish between the two, and it was confirmed that IdoA was the main uronic 
acid present in polysaccharide A. The main distinguishing feature of polysaccharide B 
with A was the presence of higher levels of fucose (>20%) and N-acetyl glucosamine 
(>35%) in B. A number of samples with mixed composition were analysed, giving 
intermediate monosaccharide composition.  
3.2 FTIR spectroscopy 
The FTIR spectrum of a sample of A. aspersa polysaccharide A in a KBr tablet is 
shown in Figure 1, overlaid with spectra from chitin and dermatan sulfate, for 
comparison. The spectrum is indicative of the structural features of a GAG like 
molecule. The peaks at 1259 cm-1 and 821 cm-1 are sulfate vibrations, multiple broad 
peaks around 1054 cm-1 are sugar ring vibrations, and the peak at 1637 cm-1 may 
combine amide vibration arising from hexosamines and C=O vibration of uronic 
acids. No attempt was made to distinguish between polysaccharides A & B by FTIR, 
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but the date shown confirms the similarity between polysaccharide A and dermatan 
sulfate, and major differences from chitin. 
 
Figure 1: (A) FITR spectrum of Polysaccharide A (black) overlaid on the spectrum (red) of reference 
dermatan sulfate (Sigma), (B) Polysaccharide A (black) overlaid on the spectrum (blue) of reference 
chitin (Sigma), all in KBr tablet. Spectrum shows absorbance plotted against wavenumber with 
absorbance maxima shown in black text for polysaccharide A 
 
3.3 NMR analysis of polysaccharide A (VRP327A) 
The monosaccharide analysis suggested that polysaccharide A is a dermatan 
sulfate. Initial 1D 1H and 13C spectra showed that the sample was too complex and 
full resonance assignment was therefore obtained using 2D 1H, 13C HSQC and 2D 1H, 
13C HSQC-TOCSY spectra. The 2D 1H, 13C HSQC-NOESY spectrum helped to 
verify the assignment and also provided information about the nature of glycosidic 
bonds. The results showed that polysaccharide A consists mainly of a highly sulfated 
disaccharide repeating unit →? 4)IdoA(1β→? 3)GalNAc 4,6SO4(1β→? In addition, 
GalNAc4SO3 and GalNAc6SO3 monosaccharides and a small amount of GlcA were 
identified in agreement with the monosaccharide analysis. The chemical shift 
comparison with similar polysaccharides showed a very good agreement with all 
identified disaccharide structural motifs in polysaccharide A (Table 4). 
 
 
 
 
Table 2. 1H/13C chemical shifts of polysaccharide A.  
 
 GalNAc4,6SO4 GalNAc4SO4 GalNAc6SO4 IdoA GlcA 
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H1/C1 4.69/105.22 4.62/105.23 4.72/104.29 4.89/106.00 4.51/107.0 
H2/C2 4.06/54.64 4.06/54.05 3.99/53.89 3.56/72.12 3.37/75.32 
H3/C3 4.05/ 78.18 4.10/78.41 3.82/83.13 3.96/73.96 3.59/76.82 
H4/C4 4.71/ 78.71 4.70/78.60 N.D. 4.08/84.07 3.75/84.52 
H5/C5 4.10/ 75.2 4.10/ 75.2 3.96/75.48 4.72/72.35 3.7/79.23 
H6/C6 4.22/ 70.65 3.78/63.88 4.22/70.27 -/176.6 -/176.73 
NAc 2.09/25.5 2.04/25.4 2.06/25.7 - - 
N.D. Not detected 
 
1H and 13C resonance assignment obtained for polysaccharide A are in a good 
agreement with the literature data; namely, the assignment of the GalNAc4,6SO4 was 
corroborated by the comparison with the corresponding data for the 4,6
 
sulfated CS[48]; 
the values for GalNAc4SO4 agreed with the mammalian DS data [49] and GalNAc6SO4 
were in agreement with the Ascidian DS data[27].  The assignment of the IdoA
 
was 
corroborated by the comparison with the corresponding data reported for a mammalian 
DS [49], while the GlcA data agreed with the porcine DS [50] and CS oligosaccharide 
data [51]. 
 
Integration of the C2 and C6 cross peaks of GalNAc4S, GalNAc6S and 
GalNAc4,6S in 2D 1H, 13C HSQC spectrum of polysaccharides A indicates that 
GalNAc4,6S constitutes approximately 75% of the total GalNAc content, whereas 
GalNAc4S and GalNAc6S constitutes the remaining 25%, approximately at 1:1 
ratio. The integration of the anomeric carbons of GlcA and IdoA showed that IdoA 
constitutes 80% of the total uronic acid content, while GlcA is only present at the 
20%.  
 
3.4 NMR analysis of polysaccharide B (VRP327B) 
The monosaccharide analysis of polysaccharide B indicated that its main 
components are N-acetylated glucosamine and fucose (2:1 ratio, Table 1). This is in 
agreement with the NMR results. Here H2/C2 resonances at 3.71-3.77/58.69-59.03 
ppm confirmed the presence of GlcNAc, as opposed to GlcNH2 for which H2 is 
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typically observed at about 0.8 ppm lower chemical shift [52]. In addition, the 1H/13C 
signals of the N-acetyl group were present at 2.04-2.16/23.25-25.49 ppm. 
Uninterrupted sequential transfer of magnetization from H1 to H6 seen in the 2D 1H, 
13C HSQC-TOCSY spectrum of polysaccharide B is a consequence of axial-axial 
arrangement of protons in GlcNAc. The analysis of 2D 1H,13C HSQC-TOCSY 
spectrum identified four distinct sets of GlcNAc resonances (M1-M4 in Table 3), 
indicating structural heterogeneity of this polysaccharide.  
Table 2: 1H/13C chemical shifts of four different GlcNAc residues and fucose residues identified for 
polysaccharide B. GlcNAc molecules M1 and M2 are branched with C3-sulfated fucose on C4, while 
GlcNAc M3 and M4 are sulfated at C4. M2 is also sulfated at C6.  
 
 GlcNAc  (M1) GlcNAc (M2) GlcNAc (M3) GlcNAc (M4) Fucose 
H1/C1 4.54/103.32 4.62/103.04 4.76/102.42 4.72/102.67 5.04/101.34 
4.92/101.56 
H2/C2 3.72/58.97 3.74/58.71 3.77/58.69 3.71/59.03 3.93/68.71 
H3/C3 4.10/78.08 4.13/78.15 4.17/80.05 4.14/79.82 4.49/80.47 
H4/C4 3.72/76.30 3.76/76.88 4.08/78.42 4.00/78.83 4.13/73.03 
H5/C5 3.43/77.48 3.68/75.59 3.70/78.28 3.60/77.46 4.75/69.29 
H6/C6 3.91/62.70 4.33-4.55/ 
65.84 
3.76-3.96/ 
64.93 
3.75-4.03/  
64.58 
1.29/18.48 
 
 
With regard to fucose, the H6/C6 resonances at 1.29/18.48 ppm confirmed the 
presence of this residue in polysaccharide B. Unlike in GlcNAc, only one set of 
fucose cross peaks were seen for H2/C2 to H6/C6 pairs, while two sets of resolved 
H1/C1 cross peaks were attributed to fucose. Comparison of 1H and 13C chemical 
shifts of fucose in polysaccharide B with those in fucosylated chondroitin sulfate 
(fCS) [40] showed that fucose of polysaccharide B is sulfated at position C3.     
 The 2D 1H, 13C HSQC-NOESY spectrum of polysaccharide B contains intra- 
and inter-residue H1-H3 cross-peaks indicating the existence of 
→3)GlcNAc(1β→3)GlcNAc(1β→ linkages. NOE cross peaks between H4 of 
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GlcNAc and H1 of fucose identified in the 2D 1H, 13C HSQC-NOESY spectrum, as 
well as the inter residue HMBC cross peak between C4 of GlcNAc and H1 of fucose, 
showed that the M1 and M2 GlcNAc residues are branched by fucose at C4 positions. 
The M1/M2 chemical shifts differ significantly only for H5/C5 and H6/C6 pairs; in 
particular the H6/C6 atoms have higher chemical shift in M2 than in M1. This 
increase is consistent with C6 sulfation of M1/M2 GlcNAc residues.   
  The 1H and 13C chemical shifts of corresponding atoms in M3 and M4 are 
very similar and their H4/C4 chemical shifts are higher than seen for M1/M2, 
indicating that in M3/M4 these positions are sulfated. A comparison with the 
chemical shifts of β-1,3 N-acetyl-glucosamine pentasaccharide [53] supports this 
conclusion.  
   Summarizing these data, it can be concluded that polysaccharide B consists 
of a β-1,3-Ν-acetyl-D-glucosamine backbone with C4 either branched with C3-
sulfated fucose (M1/M2) or sulfated (M3/M4). In M2, the C6 position of GlcNAc is 
sulfated. It is interesting to note that the H5 of fucose has high chemical shift (4.75 
ppm) which indicates that fucose is stacked above the preceding GlcNAc residue in 
the manner seen in the fCS [40]. This is also supported by NOE cross peaks seen in 
the 2D 1H, 13C HSQC-NOESY spectrum between H5, H6 of fucose and H2 of 
GlcNAc.  It is not possible to determine how these various structural motifs are 
distributed throughout polysaccharide B, but effects of neighboring residues are 
responsible for slight variation of chemical shifts e.g. M3 vs M4 and also H1/C1 of 
fucose, which enabled the presented structural analysis. These variations are likely 
caused by a different conformation adopted by a different primary structure as 
indicated by MD simulation (data not shown). Integration of isolated H5/C5 HSQC 
cross peaks allowed us to estimate the ratio of different GlcNAc types designated 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
M1:M2:M3:M4 at 22:27:27:24 %. Given the likely errors on these integrals, it is more 
appropriate to state that each occurs with equal probability.    
 
 
3.5 In vitro biochemical characteristics of the sea squirt poly- and oligo- saccharides 
VRP327A and VRP327B 
 
The biological activity (see section 3.6 for detailed description) and chemical 
composition of the sea squirt polysaccharides A and B are summarised in Table 4. 
Since, it was impossible to prepare pure samples, these data given are for the samples 
that contain both polysaccharides, but are enriched for one of the two. As mentioned 
above, VRP327A contains 83% polysaccharide A and 13% B, whereas VRP327B 
contains 20% polysaccharide A and 73% B. Both preparations were resistant to 
heparinase and chondroitinase ABC, likely because of the high sulfation of the DS 
contained in the sea squirt samples and non-GAG branched nature of polysaccharide 
B. 
 
 
 
Table 3: Summary of the in vitro biological activity, and characteristics of a range of novel marine 
GAG-like polysaccharides. 
 
ID Dominant 
(80%) 
polysaccharide 
XTT 
% 
APTT 
IU/ml 
NE 
%  
MW  
(kDa) 
 
Fucose 
molar 
% 
GlcNA
c molar 
% 
Gal 
NAc 
molar 
% 
Sulf
ate 
% 
N 
VRP327
A 
 
A  
 
100 
 
 
6.22 
 
 
37.7 
 
 
170 
 
 
3.1 
 
15.7 
 
37.3 
 
19.2 
 
8 
 
VRP327
B 
B 91.4 4.2 36.9 115 21.9 45.8 14.1 
 
17.5 2 
VRP327 
mixed 
Mixed 90.1 4.4 45.9 86.9 11.9 25.8 
 
23.0 
 
16.7  4 
VRP327A & B defined on the basis of monosaccharide composition, as confirmed by NMR. 
Data expressed as mean values from multiple different batches of polysaccharide (XTT, % 
viability relative to control; Neutrophil Elastase (NE) % activity compared with control). 
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Monosaccharide molar composition expressed as % of total monosaccharides. APTT 
represents mean values in IU/ml. N = number of samples 
 
A. aspersa polysaccharides A & B have no appreciable cellular toxicity as cells 
treated with these polysaccharides demonstrated a viability of >90 %, using XTT as a 
metabolic viability indicator. The polysaccharides were shown to have < 10 IU/mg 
anticoagulant activity, as determined by the activated partial thromboplastin time 
(APTT) assay using human plasma (Table 4). Separate analysis (data not shown) of 
one sample of polysaccharide A identified low (<1 IU / mg) antithrombin mediated 
anti-Xa and anti-IIa activity, and low heparin cofactor II inhibition of thrombin, which 
were all comparable to mammalian DS. 
 
Two polysaccharide samples were depolymerised using Fenton type free radical 
depolymerisation. The first sample was predominantly polysaccharide A (71% 
polysaccharide A, 20 % polysaccharide B). The second sample was mixed, containing 
almost equal percentages of polysaccharide A (43%) and polysaccharide B (48%). 
Oligosaccharides of various sizes were generated and tested for various biological 
activities in vitro. The degree of polymerisation (DP) of the fractions were nominally 
assigned based on the molecular weights of heparin oligosaccharide standards. The 
neutrophil elastase inhibition activity showed some correlation with chain length 
(Table 5). Cytotoxicity and anticoagulant activity of all depolymerised samples did 
not differ from that of the native polysaccharides (Table 5). The structure of the 
oligosaccharides produced from the mixed sample were analysed by NMR and it was 
found that they contained stronger signals attributable to a polysaccharide B like 
structure, rather than polysaccharide A structures (Figure 2). This indicated that the 
DS component of the sea squirt samples was preferentially depolymerised by the free 
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radical depolymerisation, probably through destruction of the IdoA monosaccharides 
and the opening of the GalNAc rings [54]. 
 
 
 
 
Table 4: The effect of various oligosaccharides on inhibition of neutrophil elastase expressed as % 
activity of each oligosaccharide compared with control (polysaccharide). 
 
Nominal DP Polysaccharide 
A NE %  
XTT 
% 
APTT 
IU/ml 
Mixed 
polysaccharide 
NE % 
XTT 
% 
APTT 
IU/ml 
Polysaccharide 38.95 96 ND 55.56 105 4.34 
Dp2 NA NA NA 129.58 ND ND 
Dp4 68.1 121 1.56 100.65 ND ND 
Dp8 66.5 130 1.95 72.71 ND ND 
Dp12 57.6 117 2.56 41.67 ND ND 
Dp16 48.7 103 2.83 62.42 ND ND 
Dp20 57.3 100 2.83 NA NA NA 
ND – Not determined. NA – Not applicable. DP – degree of polymerisation.  
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Figure 2:  Superposition of the H2/C2 region of the 2D 1H, 13C HSQC spectra of the mixture of 
polysaccharides A and B (blue), polysaccharide B rich sample (red) and the oligosaccharides 
derived from polysaccharides A and B mixture (green). The signals in the top left corner belong 
to GalNAc of polysaccharide A, whereas the signals in the bottom right corner belong to GlcNAc 
of polysaccharide B. The red and green cross peaks have been moved by 0.05 and 0.1 ppm to the 
right, respectively,  in order for their intensity to be clearly visible.  
 
 
3.6 In vitro anti-inflammatory activity of sea squirt polysaccharides and 
oligosaccharides. 
 
The anti-inflammatory activity of the sea squirt polysaccharides was demonstrated by 
measuring their effect on the release of elastase from human neutrophils and adhesion 
of human neutrophils to human umbilical cord endothelial cells (Figure 3). The 
inhibition of neutrophil elastase release is summarised in Table 4 above. Human 
neutrophils treated with polysaccharide A (VRP327A), polysaccharide B (VRP327B) 
or fucoidan (a reference polysaccharide isolated from Fucus vesiculosis) inhibited 
elastase release by 60-80 % (Figure 3a).  Transendothelial migration of neutrophils 
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was inhibited by up to 30%, which did not reach significance (Figure 3c). Similarly, 
many of the VRP327 oligosaccharides also inhibited neutrophil elastase release 
(Figure3c). However, there was no significant effect on neutrophil adhesion with any 
of the VRP327 oligosaccharides (Figure 3b). 
 
Figure 3: A,D) Percentage of elastase release from human neutrophils by the sea squirt 
polysaccharides and oligosaccharides (100 µg/ml).  Each column represents mean + SEM from N 
(left to right; 19 ,8, 4,  46, 19 respectively) separate donors performed in duplicate.  * P < 0.05 
compared with polyglutamic acid control. B) The effect of the heparin on human neutrophil 
adhesion and C) VRP327 on transmigration of human neutrophils in vitro. The results indicate 
that there is no significant reduction of adhesion of human neutrophils to human umbilical cord 
vein endothelial cells.  In contrast, migration of human neutrophils through endothelial cells 
appeared to be inhibited.  
 
 
3.4 In vivo anti-inflammatory activity of sea squirt polysaccharide A and 
oligosaccharides. 
The inflammatory stimulus, zymosan caused a neutrophil rich infiltrate 4 h after 
injection into the peritoneal cavity, with neutrophils representing 75 % of the total cell 
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population.  The administration of the polysaccharide A VRP327A by the intravenous 
route, 15 min prior to the intraperitoneal injection of zymosan, dose-dependently 
inhibited this response.  Animals exposed to VRP327A (0.1-10 mg/kg) produced a 
dose-dependent inhibition of neutrophil recruitment to the peritoneal cavity in 
response to zymosan (Figure 4A).   Fucoidan derived from F. vesiculosis (Figure 4B) 
at doses of 1 -100 mg/kg was used as a positive control and also caused a dose-
dependent inhibition of neutrophil recruitment into the peritoneal cavity after 
challenge with zymosan.  VRP327 oligosaccharides were further evaluated for their in 
vivo anti-inflammatory activity.  Dp4, dp12 and dp16 demonstrated anti-inflammatory 
activity, whilst dp8 and dp20 were less effective against neutrophil recruitment 
(Figure 4 C,D).   
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Figure 4: Inhibition of neutrophil recruitment to the peritoneal cavity.  Animals were pretreated 
intravenously with saline (zymosan only treated group), VRP327 (A) and a fucosis versiculosis 
fucoidan control (B) 15 min prior to zymosan injection.  Each column represents the mean cell 
number from 3-5 animals and vertical lines represent standard error of the mean.  * P < 0.01 
versus saline.  ^ P < 0.05 cf zymosan only (Dunnett’s post hoc test). C) Inhibitory cumulative dose 
response curves for dp4 (closed circles), dp8 (open circles) and dp16 (open diamonds) and D) 
dp12 (open circles) and dp20 (closed circles) (B) against neutrophil recruitment to the peritoneal 
cavity induced by zymosan.  The dose of VRP327x series was expressed as micromole/kg.  The 
dependent variable (% Inhibition = 100 - % control) was calculated by normalizing neutrophil 
cell number in drug treated animals by the mean neutrophil cell number in untreated animals. 
Each point is the mean + standard error of the mean of 3 animals. 
 
 
 
4. Conclusions 
 
A mixture of sulfated polysaccharides referred to as VRP327 was isolated 
from the gut of the tunicate A. aspersa. The two major polysaccharides (A and B; 
VRP327A and VRP327B) were fully characterised structurally by NMR. . The first of 
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these polysaccharides, polysaccharide A (VRP327A), is a highly sulfated dermatan 
sulfate, which contains unsulfated uronic acid and GalNAc of different sulfation 
patterns, with GalNAc 4,6S being the main component. The second polysaccharide 
(VRP327B) is a fucosylated sulfated molecule, containing a repeating 
monosaccharide unit of β-1,3-Ν-acetyl-D-glucosamine, approximately half of which 
are fucosylated on C4. These polysaccharides are interesting because they show anti-
inflammatory properties, but importantly lack significant anticoagulant activity and 
direct cytotoxicity towards mammalian cells. 
Both were shown to have anti-inflammatory activity in vitro and in vivo, while 
their anti-coagulant activity was low. Fractionation of VRP327 yielded 
oligosaccharides, which exhibited varying degrees of anti-inflammatory activity in 
vivo in the zymosan-induced neutrophilia assay.  In particular dp4, dp12 and dp16 
resulted in a dose dependent reduction in zymosan-induced neutrophilia in the 
peritoneal cavity.  The fact that these oligosaccharides lack significant anticoagulant 
activities raises the possibility of using them as low molecular weight templates in the 
search for novel anti-inflammatory drugs. 
 
 Though HPLC separation was unable to distinguish the two polysaccharide 
components of VRP327, the NMR signals of the two polysaccharides are distinct. 
Polysaccharide A is a dermatan sulfate with an unusual sulfation pattern and contains 
disulfated GalNAc 4,6 SO3, which has only been found in traces in previous Ascidian 
preparations (<1%) [27]. However, even more unique is the second polysaccharide 
isolated from A. Aspersa, which has been identified as a fucosylated chitin-like 
molecule. Whereas chitin is formed by a 1β → 4 linkage between its GlcNAc 
monomers, the GlcNAc polymer we isolated is comprised by GlcNAc linked with 1β 
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→ 3 linkage. It is also the first time that a fucosylated chitin-like polysaccharide is 
reported; previously fucosylated chitins identified being exclusively oligosaccharide 
moieties of glycoproteins. Finally both GlcNAc and fucose of polysaccharide B are 
sulfated and this polysaccharide, like other sulfated chitins [55], exhibits some 
anticoagulant activity. 
 
This observation is important because it further suggests that the anti-inflammatory 
activities of polysaccharides are independent of anticoagulant activities, supporting 
other work with heparin like molecules [11]. Previous studies have demonstrated 
inhibition of neutrophil elastase by a wide range of GAG’s [45, 56] and sulfated 
polysaccharide from seaweeds, such as fucoidan [6]. 
 
 Our initial assumption was that sulfation is required for the anti-inflammatory 
activity of the polysaccharides as has been described for other studies investigating 
the anti-proliferative and anti-secretory activity of GAGs [57]. However, further study 
of the extracts is required to fully characterise the anti-inflammatory properties of 
these novel molecules we have identified and in particular the role of sulfation. 
Nonetheless, this study clearly demonstrates that anti-inflammatory activity is present 
in polysaccharides with a very wide molecular weight range, including some of the 
small oligosaccharide derivatives of VRP327. Our results further support the concept 
that oligosaccharides from marine sources could provide a useful source of novel anti-
inflammatory molecules lacking anticoagulant activity for the treatment of diseases 
such as asthma and COPD. 
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